Minimal residual disease (MRD) levels indicated by RUNX1‐RUNX1T1 transcript levels as well as c‐KIT mutations have been demonstrated to be strong prognostic factors in t(8;21) AML.4, 5, 6, 7, 8, 9 However, their risk predictions are not perfect, and other markers have yet to be evaluated. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.